Dr Agarwals Health Care
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Dr. Agarwal's Health Care Limited is poised for sustained growth, driven by aggressive expansion and a strategic focus on premium surgical technologies. Management's commitment to adding 60 new facilities in FY27, particularly in underpenetrated markets like Delhi-NCR, aligns with the robust demand for organized eye care services, projected to grow at a 12-14% CAGR. This expansion is supported by a proprietary digital platform that enhances operational efficiency and patient outcomes. However, the company faces challenges, including initial operating losses from new facilities and a shortage of specialized medical talent, which could impact profitability in the short term. Vista's financial outlook reflects stable revenue growth and margins, with an expected upside of approximately 28.67%, indicating that the current valuation is fair relative to intrinsic value. The healthcare sector's overall growth, coupled with rising insurance coverage, provides a favorable backdrop, although potential headwinds from execution risks and market dynamics warrant close monitoring. Key opportunities include the successful integration of new facilities and the premiumization of services, while watchpoints include talent acquisition and the management of startup costs for new locations
Why We Like This Stock
- Aggressive expansion plan to add 60 new facilities in FY27, targeting high-growth markets
- Strong demand for organized eye care services, supported by a proprietary digital platform enhancing operational efficiency
- Positive market sentiment driven by premiumization of surgical services and a stable revenue growth outlook
Things To Watch Out For
- Initial operating losses from new facilities may pressure short-term profitability
- Acute shortage of specialized medical talent could hinder expansion efforts
- Execution risks associated with rapid growth and the need for continuous technology upgrades
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,332 | 1,711 | 2,080 | 2,348 | 2,811 |
| Profit Before Tax (Cr.) | 116 | 146 | 248 | 301 | 354 |
| PBT Margin | 8.7% | 8.5% | 11.9% | 12.8% | 12.6% |
| Net Profit (Cr.) | 96 | 111 | 168 | 204 | 190 |
| Earnings Per Share | 2.6 | 2.7 | 4.2 | 5.1 | 6.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Jeffries | ▲ Buy | 600 | 05-Aug-2026 |
| Morgan Stanley | ▲ Overweight | 576 | 05-Aug-2026 |
| Motilal Oswal | ▲ Buy | 610 | 08-Jun-2026 |
Company Overview
Show Company Profile
Dr. Agarwal's Health Care Limited engages in running, owning, and managing eye care hospitals, opticals, pharmacies, etc. and related services in India and internationally. It offers femto cataracts, lenticular procedure, retinal surgeries, anterior segment reconstruction, and corneal transplants, as well as refractive and other surgeries. The company also develops, designs, manufactures, imports, and exports healthcare devices, which include ophthalmic diagnostic devices, such as auto perimeter, optical biometers, and ophthalmoscopes. In addition, the company offers consultations, diagnoses, and non-surgical treatments; and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products. Dr. Agarwal's Health Care Limited was incorporated in 2010 and is based in Chennai, India.